Argus raises target for Cencora stock to USD 380.00

Published on 10/27/2026 at 11:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cencora stock costs EUR 296.35 on October 27, 2026, 0.99 percent below the Xetra close. Results are due November 4, 2026.

Targets and deal plans

Argus raised its Cencora target from USD 340.00 to USD 380.00 on October 20, 2026.
Cencora agreed to acquire American Oncology Network for USD 2.4 billion on October 21, 2026.
Cencora stock trades at EUR 296.35 at 11:02 a.m. CET at Lang & Schwarz on October 27, 2026, 0.99 percent below the Xetra close of October 26, 2026.

Cencora Inc., US03073E1055, Illustration mit AI erstellt.

Cencora stock (ISIN US03073E1055) costs EUR 296.35 at Lang & Schwarz on October 27, 2026, 0.99 percent below the Xetra close of October 26, 2026. MarketBeat reported that Argus raised its target from USD 340.00 to USD 380.00 on October 20, 2026.

Why the oncology deal matters

Cencora announced on October 21, 2026, that it had signed an agreement to acquire American Oncology Network, a physician-led network with more than 350 oncology providers across 21 states. The transaction values AON at USD 2.4 billion, including USD 2.3 billion at closing and contingent value rights of up to USD 100.0 million, according to the Cencora release.

Cencora expects to pay approximately USD 1.7 billion at closing if certain AON investors retain a 25 percent equity rollover. The company also expects the acquisition to add to adjusted diluted earnings per share in the second year after closing, although regulatory clearances and shareholder approvals remain conditions of completion.

What does the guidance show?

On October 22, 2026, Cencora lifted the floor for fiscal 2026 adjusted diluted earnings per share to USD 17.90, the high end of its previous USD 17.75 to USD 17.95 range, according to Markets Insider. In the third quarter of fiscal 2026, revenue reached USD 84.75 billion, up 5.1 percent year over year, while adjusted earnings per share were USD 4.48 against a USD 4.35 consensus estimate, MarketBeat reported.

Three events shape the timeline

On October 20, 2026, Argus raised its target to USD 380.00 from USD 340.00. On October 21, 2026, Cencora agreed to the USD 2.4 billion AON transaction. On October 22, 2026, the company set the fiscal 2026 adjusted earnings-per-share floor at USD 17.90.

When are results due?

Cencora plans to release fourth-quarter fiscal 2026 results before the New York Stock Exchange opens on November 4, 2026, followed by an 8:30 a.m. ET conference call, according to the Cencora release. The date gives investors the next hard test for the USD 17.90 guidance floor and the integration case behind the oncology acquisition.

Stock price and valuation

Cencora is listed on the NYSE under ticker COR. MarketBeat cited a USD 63.1 billion market capitalization and a USD 244.82 to USD 377.54 52-week range as of October 26, 2026. At Lang & Schwarz, the stock was trading at EUR 296.35 on October 27, 2026, at 11:02 a.m. CET, 0.99 percent below the Xetra close of October 26, 2026, at EUR 299.30. The further course of trading is shown by the continuously updated real-time quote of Cencora stock.